These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 6430321)
41. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Memin Y Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796 [TBL] [Abstract][Full Text] [Related]
42. Cyclandelate in diabetic radiculoneuropathy. van der Drift JH Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764 [No Abstract] [Full Text] [Related]
43. Effect of cyclandelate on perception, memory and cognition in a group of geriatric subjects. Aderman M; Giardina WJ; Koreniowski S J Am Geriatr Soc; 1972 Jun; 20(6):268-71. PubMed ID: 4555668 [No Abstract] [Full Text] [Related]
44. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice. de Halleux F Drugs; 1987; 33 Suppl 2():114-9. PubMed ID: 3622305 [TBL] [Abstract][Full Text] [Related]
45. Biphasic initial phase of platelet aggregation inhibition after oral aspirin. Walter E; Zimmermann R; Siess R; Staiger C; Weber E Artery; 1980; 8(5):501-6. PubMed ID: 7213053 [TBL] [Abstract][Full Text] [Related]
46. Cyclandelate in the treatment of cerebral arteriosclerosis. Hall P J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704 [TBL] [Abstract][Full Text] [Related]
47. Platelet aggregation: inhibition of secondary aggregation by phenol. Coan ML; Case KR; Bosmann HB Res Commun Chem Pathol Pharmacol; 1982 May; 36(2):241-9. PubMed ID: 6808618 [TBL] [Abstract][Full Text] [Related]
48. [Cyclospasmol (mandelic acid ester of 3,5,5-trimethylcyclohexanol) in therapy of skin diseases]. DOORNINK FJ Geneeskd Gids; 1953 Jun; 31(12):247-51. PubMed ID: 13083900 [No Abstract] [Full Text] [Related]
49. Effects of acute, moderate ethanol consumption on human platelet aggregation in platelet-rich plasma and whole blood. Zhang QH; Das K; Siddiqui S; Myers AK Alcohol Clin Exp Res; 2000 Apr; 24(4):528-34. PubMed ID: 10798590 [TBL] [Abstract][Full Text] [Related]
50. The treatment of peripheral vascular diseases with cyclospasmol (mandelic acid ester of 3, 5, 5-trimethylcyclohexanol). VAN WIJK TW Angiology; 1953 Apr; 4(2):103-13. PubMed ID: 13040814 [No Abstract] [Full Text] [Related]
51. Effects of acetylsalicylic acid on human platelet function in vivo at salicylate steady state. Simrock R; Missalla A; Schwidtal P; Lischke V; Breddin HK Thromb Haemost; 1984 Apr; 51(2):269-71. PubMed ID: 6740559 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511 [TBL] [Abstract][Full Text] [Related]
57. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders. Albizzati MG; Bassi S; Sbacchi M; Frattola L Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327 [No Abstract] [Full Text] [Related]
58. Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist. Freed MI; Boike S; Zariffa N; Jorkasky DK Thromb Haemost; 1994 Oct; 72(4):622-6. PubMed ID: 7878642 [TBL] [Abstract][Full Text] [Related]
59. The clinical efficacy of Cyclospasmol: a review of the literature. Blakemore CB Br J Clin Pract Suppl; 1984; 34():3-9. PubMed ID: 6430319 [No Abstract] [Full Text] [Related]